High plasma levels of intact and cleaved soluble urokinase receptor reflect immune activation and are independent predictors of morality in HIV-1-infected patients
Article Abstract:
A study investigates the plasma levels off soluble urokinase type plasminogen activator [suPAR](I-III), suPAR (II-III), and 1-domain suPAR [suPAR (I)] and their predictive value for survival in HIV patients. Conclusions reveal that plasma levels of different suPAR forms are increased and associated with immune activation in HIV patients, and suPAR (I-III) and suPAR (II-III) are independent predictions of mortality in these patients.
Publication Name: Journal of Acquired Immune Deficiency Syndromes (1999)
Subject: Health
ISSN: 1525-4135
Year: 2005
User Contributions:
Comment about this article or add new information about this topic:
Immune function and phenotype before and after Highly Active Antiretroviral Therapy (HAART)
Article Abstract:
The authors point to the results of their study, verifying immune fucntions through CD4 counts 30 months prior to and 17 months after highly active antiretroviral therapy (HAART). They learned that HAART aggressively reduces the viral load, but that after therapy is halted, the remaining cells reproduce much faster than before to restore the viral load.
Publication Name: Journal of Acquired Immune Deficiency Syndromes (1999)
Subject: Health
ISSN: 1525-4135
Year: 1999
User Contributions:
Comment about this article or add new information about this topic:
Soluble urokinase receptor levels in plasma during 5 years of highly active antiretroviral therapy in HIV-1-infected patients
Article Abstract:
The plasma concentration of suPAR (soluble urokinase receptor) in 29 treatment-naive HIV-1-infected patients during 5 years treatment with highly active antiretroviral therapy (HAART) is examined. The results revealed that the blood levels of suPAR is linked to inflammation and immune activation in untreated as well as HAART-treated HIV-1 patients.
Publication Name: Journal of Acquired Immune Deficiency Syndromes (1999)
Subject: Health
ISSN: 1525-4135
Year: 2004
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Prescribing of contraindicated protease inhibitor and statin combinations among HIV-infected persons. Implications of T-cell P-glycoprotein activity during HIV-1 infection and its therapy
- Abstracts: Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Molecular determinants of resistance to antiandrogen therapy
- Abstracts: Serious adverse coetaneous and hepatic toxicities associated with Nevirapine use by non-HIV-infected individuals
- Abstracts: Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Clues for new therapeutics in osteoporosis
- Abstracts: A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. Adjuvant therapy for pancreatic cancer-the debate continues